Edition:
India

Soleno Therapeutics Inc (SLNO.OQ)

SLNO.OQ on NASDAQ Stock Exchange Capital Market

1.60USD
17 Nov 2017
Change (% chg)

$-0.23 (-12.57%)
Prev Close
$1.83
Open
$1.78
Day's High
$1.80
Day's Low
$1.58
Volume
22,558
Avg. Vol
7,976
52-wk High
$6.50
52-wk Low
$1.48

Latest Key Developments (Source: Significant Developments)

Soleno Therapeutics posts Q3 loss $0.24/shr from continuing operations
Tuesday, 14 Nov 2017 

Nov 14 (Reuters) - Soleno Therapeutics Inc :Soleno Therapeutics provides corporate update and reports third quarter 2017 financial results.Q3 loss per share $0.24 from continuing operations.Q3 loss per share $0.35.  Full Article

Capnia Q2 loss per share $0.23
Saturday, 13 Aug 2016 

Capnia Inc : Q2 loss per share $0.23 .Capnia reports second quarter 2016 financial results.  Full Article

Capnia says distribution agreement for CoSense monitor in India
Wednesday, 8 Jun 2016 

Capnia Inc : Capnia announces exclusive distribution agreement for CoSense® End-Tidal Carbon Monoxide monitor in India . Under terms, Healthware will be responsible for all sales and related activities supporting distribution of CoSense in India .Sales of CoSense to Healthware will commence immediately.  Full Article

Capnia reports Q1 loss of $0.22 per share
Tuesday, 10 May 2016 

Capnia Inc : Says total revenue recognized in three months ended march 31, 2016 was $447,000 as compared to $22,000 in same period in 2015 . Capnia reports first quarter 2016 financial results .Q1 loss per share $0.22.  Full Article

Capnia signs distribution agreement with Bemes Inc
Wednesday, 27 Jan 2016 

Capnia Inc:Says announced that it has entered into an exclusive distribution agreement with Bemes Inc.Under the agreement, Bemes will have the exclusive right for sales, marketing, distribution and field service activities for CoSense in the United States.  Full Article

Capnia, Inc granted Orphan Designation for Nasal CO2 for the treatment of Trigeminal Neuralgia
Monday, 21 Dec 2015 

Capnia, Inc:Granted orphan designation for nasal co2 for the treatment of trigeminal neuralgia.  Full Article

BRIEF-Soleno Therapeutics posts Q3 loss $0.24/shr from continuing operations

* Soleno Therapeutics provides corporate update and reports third quarter 2017 financial results